1. Home
  2. SAFT vs EVO Comparison

SAFT vs EVO Comparison

Compare SAFT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

HOLD

Current Price

$72.26

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.95

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFT
EVO
Founded
1979
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
SAFT
EVO
Price
$72.26
$1.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
117.9K
39.3K
Earning Date
05-05-2026
04-08-2026
Dividend Yield
4.88%
N/A
EPS Growth
40.17
N/A
EPS
N/A
N/A
Revenue
$1,263,732,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
12.83
N/A
52 Week Low
$67.04
$1.95
52 Week High
$81.49
$4.42

Technical Indicators

Market Signals
Indicator
SAFT
EVO
Relative Strength Index (RSI) 41.45 24.13
Support Level $70.76 N/A
Resistance Level $73.60 $3.36
Average True Range (ATR) 1.64 0.10
MACD -0.49 -0.07
Stochastic Oscillator 2.16 2.02

Price Performance

Historical Comparison
SAFT
EVO

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: